Sarepta And Roche Press Ahead With Elevidys Filing Despite Duchenne Trial Miss

The Phase III EMBARK study has fallen short on its primary endpoint – but Sarepta believes the trial has otherwise produced robust data, and believes a full US approval is justified.

Sarepta Building 2

Sarepta Therapeutics is to seek full approval for its Duchenne gene therapy Elevidys in the US and partners Roche have likewise vowed to seek approval in ex-US countries, despite it failing to hit the primary endpoint of its Phase III study.

Elevidys (delandistrogene moxeparvovec-rokl) gained an accelerated US Food and Drug Administration approval in June to treat ambulatory patients ages four...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip